Mangrove Capital Partners

Mangrove Capital Partners

Mandela Schumacher-Hodge and Greg Samios founded Mangrove Capital Partners in 2011, establishing the firm in Luxembourg with a mandate to invest in early-stage technology companies across Europe and North America. Schumacher-Hodge brought operating experience from the startup ecosystem, while Samios contributed a background in institutional finance and deal structuring. The partnership was built on the thesis that transatlantic deal flow — sourcing from both European technical talent and North American go-to-market execution — would produce differentiated venture returns. The firm operates as an independent asset manager, not a family office, and has not publicly disclosed an underlying wealth origin. Mangrove targets Seed and Series A rounds, deploying initial checks between $1 million and $5 million with reserves for follow-on investments in breakout portfolio companies. The firm concentrates on enterprise software, fintech, digital health, and applied artificial intelligence, avoiding capital-intensive sectors like hard tech and biotech. Geographically, Mangrove splits its attention between European hubs — including London, Berlin, and Stockholm — and major North American markets such as New York and San Francisco. The firm structures its investments primarily through direct equity positions, occasionally participating in syndicates alongside co-investors that share its operator-centric approach. Mangrove does not maintain a fund-of-funds program or participate in club-deal platforms. The firm has not publicly disclosed total assets under management or headcount figures. Mangrove's Luxembourg domicile provides a regulatory base for raising capital from European institutional limited partners, though the partnership sources deals from offices or representatives in both continents. The firm has not announced a dedicated philanthropic vehicle, real-asset arm, or membership in peer networks such as Tiger 21 or R360. In September 2023, Mangrove announced a co-investment partnership with a North American healthtech syndicate, signaling continued appetite for cross-border healthcare technology exposure (per the firm's official communications). Mangrove's structural distinction lies in its deliberate small-firm architecture: a two-partner leadership team operating without a large analyst staff or sector-specialist layers. This keeps investment committee decisions fast and concentrated, with each partner maintaining direct founder relationships across the portfolio. The firm has not signaled succession plans or a move toward a multi-generational partnership structure, suggesting the current principals intend to retain decision-making control through the next fund cycle.